Skip to content
Screener

Kymera Therapeutics KYMR Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$204.43M+73.1%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$72.39M-2.7%
Pfizer logo
PfizerPFE
——
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
——
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
——
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
——

Other financials

Income statement

See full
Revenue$65.0M+466%
Operating income-$75.6M+10.6%
Net income-$61.2M+20.1%
EPS (diluted)-$0.62+34.7%

Balance sheet

See full
Cash & equivalents$124.5M-62.9%
Total debt$80.1M-8.5%
Total equity$1.5B+55.4%
Total assets$1.6B+45.5%

Cash flow

See full
Operating cash flow-$54.1M+9.7%
CapEx$473.0K-31.9%
Free cash flow-$54.5M+10.0%

Valuation

See full
Market cap$8.68B+199%
Enterprise value$8.63B+225%
P/S82.6×+17.8×

Profitability

See full
Operating margin-333.5%-114pp
Net margin-285.3%-99.7pp
FCF margin-226.6%-84.9pp

Returns & leverage

See full
Return on equity-24.2%-5.2pp
Debt / equity0.1×0.0×
Current ratio10.3×+2.0×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:15 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333849
Line itemJune 30,2026December 31,2025
Assets
Current assets:
Cash and cash equivalents$124,477$357,011
Marketable securities (Note 4)566,508491,265
Accounts receivable20,000—
Prepaid expenses and other current assets26,28022,938
Total current assets$737,265$871,214
Marketable securities, non-current (Note 4)813,901771,158

Item 1. Financial Statements.

FAQ

What is Kymera Therapeutics's available for sale securities debt securities current?
Kymera Therapeutics (KYMR) reported available for sale securities debt securities current of $566.51M in Q2 2026.
How has Kymera Therapeutics's available for sale securities debt securities current changed year-over-year?
Kymera Therapeutics's available for sale securities debt securities current increased by 71.9% year-over-year, from $329.63M to $566.51M.
What is the long-term trend for Kymera Therapeutics's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Kymera Therapeutics's available for sale securities debt securities current has grown at a 13.1% compound annual growth rate (CAGR), from $265.2M to $491.27M.
What does available for sale securities debt securities current mean?
Available For Sale Securities Debt Securities Current

Ask your AI about Kymera Therapeutics's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude